Alzamend Neuro, INC. (ALZN) — 10-Q Filings

10-Q Filings (6)

• Alzamend Neuro's Losses Mount Amid R&D Surge, Going Concern Doubts — Dec 9, 2025 Risk: high
  Alzamend Neuro, Inc. (ALZN) reported a net loss of $1.0 million for the three months ended October 31, 2025, a decrease from $1.4 million in the same period of
• Alzamend Neuro's R&D Soars, Net Loss Triples Amid Reverse Splits — Sep 10, 2025 Risk: high
  Alzamend Neuro, Inc. (ALZN) reported a significant increase in net loss for the three months ended July 31, 2025, reaching $2,702,684, a substantial rise from $
• Alzamend Neuro Files 10-Q, Details Financials — Mar 10, 2025 Risk: medium
  Alzamend Neuro, Inc. filed a 10-Q for the period ending January 31, 2025. The company's fiscal year ends on April 30th. The filing details financial information
• Alzamend Neuro Files 10-Q for Q2 2024 — Dec 11, 2024 Risk: medium
  Alzamend Neuro, Inc. filed its 10-Q for the period ending October 31, 2024. The company reported financial results and provided updates on its business operatio
• Alzamend Neuro Files 10-Q for Period Ending July 31, 2024 — Sep 11, 2024 Risk: medium
  Alzamend Neuro, Inc. filed a 10-Q for the period ending July 31, 2024. The company reported its financial results and provided updates on its business operation
• Alzamend Neuro, Inc. Files 10-Q for Period Ending January 31, 2024 — Mar 25, 2024 Risk: medium
  Alzamend Neuro, Inc. (ALZN) filed a Quarterly Report (10-Q) with the SEC on March 25, 2024. Alzamend Neuro, Inc. filed a 10-Q report for the period ending Janua

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX